Seoul National University Hospital Partners with Institute of Biotechnology to Lead Advanced Bio Development

Seoul National University Hospital announced on the 19th that it has signed a memorandum of understanding (MOU) with the Korea Research Institute of Bioscience and Biotechnology (KRIBB) to "promote and develop national strategic technology (advanced bio) research."

Seoul National University Hospital announced on the 19th that it has signed a memorandum of understanding with the Korea Research Institute of Bioscience and Biotechnology to "promote and develop national strategic technology (advanced bio) research." Kim Young-tae, Director of Seoul National University Hospital (left), and Kim Jang-sung, Director of the Korea Research Institute of Bioscience and Biotechnology, are taking a commemorative photo after signing the agreement.
[Photo by Seoul National University Hospital]

National strategic technology refers to technologies that are strategically important from the perspectives of economy, diplomacy, and security. Among them, the advanced bio sector, represented by gene and cell therapy and digital healthcare, is explained by the hospital as having high growth potential through integration with advanced technologies such as artificial intelligence (AI).

The purpose of this agreement is to create an advanced bio research ecosystem by combining Seoul National University Hospital’s clinical research and advanced digital health capabilities with KRIBB’s foundational bio research. Furthermore, the two institutions plan to strengthen domestic industry-academia-research-hospital collaboration centered on them and expand global research and development (R&D) cooperation.

To this end, the two institutions will mutually cooperate in ▲ advancing R&D in the advanced bio field by linking KRIBB’s foundational R&D with Seoul National University Hospital’s research and clinical capabilities ▲ expanding and accelerating cooperation with global research institutions ▲ jointly utilizing research resources such as data, genomics, equipment, and facilities for advanced bio R&D ▲ and fostering specialized personnel.

Kim Jang-sung, President of the Korea Research Institute of Bioscience and Biotechnology, said, "I hope this collaboration will serve as a starting point to elevate the qualitative level of the domestic bio sector by combining the strengths of the two institutions and ultimately produce world-class research outcomes." He added, "We will strive to establish the R&D-clinical linkage model as the core of the domestic industry-academia-research-hospital bio consortium to lead the development of advanced bio."

Kim Young-tae, President of Seoul National University Hospital, said, "Advanced bio technologies such as gene and cell therapy and AI-based new drug development will be an important strategy to realize a healthy and happy life for humanity as a foundation for the advancement of treatments for severe, rare, and intractable diseases." He added, "Seoul National University Hospital will maximize its basic, translational, and clinical research capabilities to secure competitiveness in advanced medical science together with KRIBB and will do its best to establish a global bio cluster."

Meanwhile, the signing ceremony held on the day was attended by Kim Young-tae, President of Seoul National University Hospital; Kim Jang-sung, President of the Korea Research Institute of Bioscience and Biotechnology; and Kim Yong-jin, Director of the Biomedical Research Institute at Seoul National University Hospital.

This content was produced with the assistance of AI translation services.